Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016

B. Rossetti; Barbara Rossetti; Simona Di Giambenedetto; C. Torti; M. C. Postorino; G. Punzi; F. Saladini; W. Gennari; V. Borghi; L. Monno; A. R. Pignataro; E. Polilli; Manuela Colafigli; A. Poggi; S. Tini; M. Zazzi; A. De Luca; Andrea De Luca; Vincenzo Mellace; Amedeo Capetti; Maria Rita Gismondo; Maria Luisa Biondi; Cristina Mussini; Monica Pecorari; Nicola Gianotti; Daria Sacchini; Giustino Parruti; Franco Baldelli; Stefania Zanussi; Alessandro Nerli; Lucia Lenzi; Carlo Calzetti; Angela Vivarelli; Renato Maserati; Fausto Baldanti; Federica Poletti; Vincenzo Mondino; Marina Malena; Antonio Cascio; Gaetano Filice; Giacomo Magnani; Alessandro Zerbini; Francesca Lombardi; Simona Di Gaimbenedetto; Massimo Andreoni; Marco Montano; Vincenzo Vullo; Ombretta Turriziani; Angela Gonnelli; Enzo Boeri; Stefano Bonora; Valeria Ghisetti; Daniela Francisci; Paolo Grossi; Patrizia Bagnarelli; Luca Butini; Romana Del Gobbo; Andrea Giacometti; Danilo Tacconi; Annapaola Callegaro; Franco Maggiolo; Alessia Zoncada; Elisabetta Paolini; Laura Sighinolfi; Grazia Colao; Paola Corsi; Pierluigi Blanc; Luisa Galli; Paola Meraviglia; Andrea Tosti; Bianca Bruzzone; Maurizio Setti; Giovanni Penco; Antonio Di Biagio; Cesira Nencioni; Riccardo Pardelli; Irene Arcidiacono; Alberto Degiuli; Michele De Gennaro; Alessandro Soria; Alfredo Foc; Surace Latella; Lucio Cosco; Sergio Malandrin; Paola Milini; Paola Cicconi; Stefano Rusconi; Valeria Micheli

doi:10.1111/hiv.12640

Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016

B. Rossetti, Barbara Rossetti, Simona Di Giambenedetto, C. Torti, M. C. Postorino, G. Punzi, F. Saladini, W. Gennari, V. Borghi, L. Monno, A. R. Pignataro, E. Polilli, Manuela Colafigli, A. Poggi, S. Tini, M. Zazzi, A. De Luca, Andrea De Luca, Vincenzo Mellace, Amedeo CapettiMaria Rita Gismondo, Maria Luisa Biondi, Cristina Mussini, Monica Pecorari, Nicola Gianotti, Daria Sacchini, Giustino Parruti, Franco Baldelli, Stefania Zanussi, Alessandro Nerli, Lucia Lenzi, Carlo Calzetti, Angela Vivarelli, Renato Maserati, Fausto Baldanti, Federica Poletti, Vincenzo Mondino, Marina Malena, Antonio Cascio, Gaetano Filice, Giacomo Magnani, Alessandro Zerbini, Francesca Lombardi, Simona Di Gaimbenedetto, Massimo Andreoni, Marco Montano, Vincenzo Vullo, Ombretta Turriziani, Angela Gonnelli, Enzo Boeri, Stefano Bonora, Valeria Ghisetti, Daniela Francisci, Paolo Grossi, Patrizia Bagnarelli, Luca Butini, Romana Del Gobbo, Andrea Giacometti, Danilo Tacconi, Annapaola Callegaro, Franco Maggiolo, Alessia Zoncada, Elisabetta Paolini, Laura Sighinolfi, Grazia Colao, Paola Corsi, Pierluigi Blanc, Luisa Galli, Paola Meraviglia, Andrea Tosti, Bianca Bruzzone, Maurizio Setti, Giovanni Penco, Antonio Di Biagio, Cesira Nencioni, Riccardo Pardelli, Irene Arcidiacono, Alberto Degiuli, Michele De Gennaro, Alessandro Soria, Alfredo Foc, Surace Latella, Lucio Cosco, Sergio Malandrin, Paola Milini, Paola Cicconi, Stefano Rusconi, Valeria Micheli

Risultato della ricerca: Contributo in rivista › Articolo in rivista

15 Citazioni (Scopus)

Abstract

Objectives: The aim was to evaluate the evolution of transmitted HIV-1 drug resistance (TDR) prevalence in antiretroviral therapy (ART)-naïve patients from 2006 to 2016. Methods: HIV-1 sequences were retrieved from the Antiviral Response Cohort Analysis (ARCA) database and TDR was defined as detection of at least one mutation from the World Health Organization (WHO) surveillance list. Results: We included protease/reverse transcriptase sequences from 3573 patients; 455 had also integrase sequences. Overall, 68.1% of the patients were Italian, the median CD4 count was 348 cells/μL [interquartile range (IQR) 169–521 cells/μL], and the median viral load was 4.7 log10 HIV-1 RNA copies/mL (IQR 4.1–5.3 log10 copies/mL). TDR was detected in 10.3% of patients: 6% carried mutations to nucleos(t)ide reverse transcriptase inhibitors (NRTIs), 4.4% to nonnucleos(t)ide reverse transcriptase inhibitors (NNRTIs), 2.3% to protease inhibitors (PIs), 0.2% to integrase strand transfer inhibitors (INSTIs) and 2.1% to at least two drug classes. TDR declined from 14.5% in 2006 to 7.3% in 2016 (P = 0.003): TDR to NRTIs from 9.9 to 2.9% (P = 0.003) and TDR to NNRTIs from 5.1 to 3.7% (P = 0.028); PI TDR remained stable. The proportion carrying subtype B virus declined from 76.5 to 50% (P < 0.001). The prevalence of TDR was higher in subtype B vs. non-B (12.6 vs. 4.9%, respectively; P < 0.001) and declined significantly in subtype B (from 17.1 to 8.8%; P = 0.04) but not in non-B subtypes (from 6.1 to 5.8%; P = 0.44). Adjusting for country of origin, predictors of TDR were subtype B [adjusted odds ratio (AOR) for subtype B vs. non-B 2.91; 95% confidence interval (CI) 1.93–4.39; P < 0.001], lower viral load (per log10 higher: AOR 0.86; 95% CI 0.75–0.99; P = 0.03), site in northern Italy (AOR for southern Italy/island vs. northern Italy, 0.61; 95% CI 0.40–0.91; P = 0.01), and earlier calendar year (per 1 year more recent: AOR 0.95; 95% CI 0.91–0.99; P = 0.02). Conclusions: The prevalence of HIV-1 TDR has declined during the last 10 years in Italy.

Lingua originale	English
pagine (da-a)	619-628
Numero di pagine	10
Rivista	HIV Medicine
Volume	19
DOI	https://doi.org/10.1111/hiv.12640
Stato di pubblicazione	Pubblicato - 2018

Keywords

HIV
Health Policy
Infectious Diseases
Pharmacology (medical)
antiretroviral therapy
recent HIV infection
resistance epidemiology
transmitted HIV drug resistance

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1111/hiv.12640

Altri file e collegamenti

Cita questo

Rossetti, B., Rossetti, B., Di Giambenedetto, S., Torti, C., Postorino, M. C., Punzi, G., Saladini, F., Gennari, W., Borghi, V., Monno, L., Pignataro, A. R., Polilli, E., Colafigli, M., Poggi, A., Tini, S., Zazzi, M., De Luca, A., De Luca, A., Mellace, V., ... Micheli, V. (2018). Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016. HIV Medicine, 19, 619-628. https://doi.org/10.1111/hiv.12640

@article{c8ee83058c164dac99f85ea989075426,

title = "Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016",

abstract = "Objectives: The aim was to evaluate the evolution of transmitted HIV-1 drug resistance (TDR) prevalence in antiretroviral therapy (ART)-na{\"i}ve patients from 2006 to 2016. Methods: HIV-1 sequences were retrieved from the Antiviral Response Cohort Analysis (ARCA) database and TDR was defined as detection of at least one mutation from the World Health Organization (WHO) surveillance list. Results: We included protease/reverse transcriptase sequences from 3573 patients; 455 had also integrase sequences. Overall, 68.1% of the patients were Italian, the median CD4 count was 348 cells/μL [interquartile range (IQR) 169–521 cells/μL], and the median viral load was 4.7 log10 HIV-1 RNA copies/mL (IQR 4.1–5.3 log10 copies/mL). TDR was detected in 10.3% of patients: 6% carried mutations to nucleos(t)ide reverse transcriptase inhibitors (NRTIs), 4.4% to nonnucleos(t)ide reverse transcriptase inhibitors (NNRTIs), 2.3% to protease inhibitors (PIs), 0.2% to integrase strand transfer inhibitors (INSTIs) and 2.1% to at least two drug classes. TDR declined from 14.5% in 2006 to 7.3% in 2016 (P = 0.003): TDR to NRTIs from 9.9 to 2.9% (P = 0.003) and TDR to NNRTIs from 5.1 to 3.7% (P = 0.028); PI TDR remained stable. The proportion carrying subtype B virus declined from 76.5 to 50% (P < 0.001). The prevalence of TDR was higher in subtype B vs. non-B (12.6 vs. 4.9%, respectively; P < 0.001) and declined significantly in subtype B (from 17.1 to 8.8%; P = 0.04) but not in non-B subtypes (from 6.1 to 5.8%; P = 0.44). Adjusting for country of origin, predictors of TDR were subtype B [adjusted odds ratio (AOR) for subtype B vs. non-B 2.91; 95% confidence interval (CI) 1.93–4.39; P < 0.001], lower viral load (per log10 higher: AOR 0.86; 95% CI 0.75–0.99; P = 0.03), site in northern Italy (AOR for southern Italy/island vs. northern Italy, 0.61; 95% CI 0.40–0.91; P = 0.01), and earlier calendar year (per 1 year more recent: AOR 0.95; 95% CI 0.91–0.99; P = 0.02). Conclusions: The prevalence of HIV-1 TDR has declined during the last 10 years in Italy.",

keywords = "HIV, Health Policy, Infectious Diseases, Pharmacology (medical), antiretroviral therapy, recent HIV infection, resistance epidemiology, transmitted HIV drug resistance, HIV, Health Policy, Infectious Diseases, Pharmacology (medical), antiretroviral therapy, recent HIV infection, resistance epidemiology, transmitted HIV drug resistance",

author = "B. Rossetti and Barbara Rossetti and {Di Giambenedetto}, Simona and C. Torti and Postorino, {M. C.} and G. Punzi and F. Saladini and W. Gennari and V. Borghi and L. Monno and Pignataro, {A. R.} and E. Polilli and Manuela Colafigli and A. Poggi and S. Tini and M. Zazzi and {De Luca}, A. and {De Luca}, Andrea and Vincenzo Mellace and Amedeo Capetti and Gismondo, {Maria Rita} and Biondi, {Maria Luisa} and Cristina Mussini and Monica Pecorari and Nicola Gianotti and Daria Sacchini and Giustino Parruti and Franco Baldelli and Stefania Zanussi and Alessandro Nerli and Lucia Lenzi and Carlo Calzetti and Angela Vivarelli and Renato Maserati and Fausto Baldanti and Federica Poletti and Vincenzo Mondino and Marina Malena and Antonio Cascio and Gaetano Filice and Giacomo Magnani and Alessandro Zerbini and Francesca Lombardi and {Di Gaimbenedetto}, Simona and Massimo Andreoni and Marco Montano and Vincenzo Vullo and Ombretta Turriziani and Angela Gonnelli and Enzo Boeri and Stefano Bonora and Valeria Ghisetti and Daniela Francisci and Paolo Grossi and Patrizia Bagnarelli and Luca Butini and {Del Gobbo}, Romana and Andrea Giacometti and Danilo Tacconi and Annapaola Callegaro and Franco Maggiolo and Alessia Zoncada and Elisabetta Paolini and Laura Sighinolfi and Grazia Colao and Paola Corsi and Pierluigi Blanc and Luisa Galli and Paola Meraviglia and Andrea Tosti and Bianca Bruzzone and Maurizio Setti and Giovanni Penco and {Di Biagio}, Antonio and Cesira Nencioni and Riccardo Pardelli and Irene Arcidiacono and Alberto Degiuli and {De Gennaro}, Michele and Alessandro Soria and Alfredo Foc and Surace Latella and Lucio Cosco and Sergio Malandrin and Paola Milini and Paola Cicconi and Stefano Rusconi and Valeria Micheli",

year = "2018",

doi = "10.1111/hiv.12640",

language = "English",

volume = "19",

pages = "619--628",

journal = "HIV Medicine",

issn = "1464-2662",

publisher = "Blackwell Science",

}

Rossetti, B, Rossetti, B, Di Giambenedetto, S, Torti, C, Postorino, MC, Punzi, G, Saladini, F, Gennari, W, Borghi, V, Monno, L, Pignataro, AR, Polilli, E, Colafigli, M, Poggi, A, Tini, S, Zazzi, M, De Luca, A, De Luca, A, Mellace, V, Capetti, A, Gismondo, MR, Biondi, ML, Mussini, C, Pecorari, M, Gianotti, N, Sacchini, D, Parruti, G, Baldelli, F, Zanussi, S, Nerli, A, Lenzi, L, Calzetti, C, Vivarelli, A, Maserati, R, Baldanti, F, Poletti, F, Mondino, V, Malena, M, Cascio, A, Filice, G, Magnani, G, Zerbini, A, Lombardi, F, Di Gaimbenedetto, S, Andreoni, M, Montano, M, Vullo, V, Turriziani, O, Gonnelli, A, Boeri, E, Bonora, S, Ghisetti, V, Francisci, D, Grossi, P, Bagnarelli, P, Butini, L, Del Gobbo, R, Giacometti, A, Tacconi, D, Callegaro, A, Maggiolo, F, Zoncada, A, Paolini, E, Sighinolfi, L, Colao, G, Corsi, P, Blanc, P, Galli, L, Meraviglia, P, Tosti, A, Bruzzone, B, Setti, M, Penco, G, Di Biagio, A, Nencioni, C, Pardelli, R, Arcidiacono, I, Degiuli, A, De Gennaro, M, Soria, A, Foc, A, Latella, S, Cosco, L, Malandrin, S, Milini, P, Cicconi, P, Rusconi, S & Micheli, V 2018, 'Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016', HIV Medicine, vol. 19, pagg. 619-628. https://doi.org/10.1111/hiv.12640

TY - JOUR

T1 - Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016

AU - Rossetti, B.

AU - Rossetti, Barbara

AU - Di Giambenedetto, Simona

AU - Torti, C.

AU - Postorino, M. C.

AU - Punzi, G.

AU - Saladini, F.

AU - Gennari, W.

AU - Borghi, V.

AU - Monno, L.

AU - Pignataro, A. R.

AU - Polilli, E.

AU - Colafigli, Manuela

AU - Poggi, A.

AU - Tini, S.

AU - Zazzi, M.

AU - De Luca, A.

AU - De Luca, Andrea

AU - Mellace, Vincenzo

AU - Capetti, Amedeo

AU - Gismondo, Maria Rita

AU - Biondi, Maria Luisa

AU - Mussini, Cristina

AU - Pecorari, Monica

AU - Gianotti, Nicola

AU - Sacchini, Daria

AU - Parruti, Giustino

AU - Baldelli, Franco

AU - Zanussi, Stefania

AU - Nerli, Alessandro

AU - Lenzi, Lucia

AU - Calzetti, Carlo

AU - Vivarelli, Angela

AU - Maserati, Renato

AU - Baldanti, Fausto

AU - Poletti, Federica

AU - Mondino, Vincenzo

AU - Malena, Marina

AU - Cascio, Antonio

AU - Filice, Gaetano

AU - Magnani, Giacomo

AU - Zerbini, Alessandro

AU - Lombardi, Francesca

AU - Di Gaimbenedetto, Simona

AU - Andreoni, Massimo

AU - Montano, Marco

AU - Vullo, Vincenzo

AU - Turriziani, Ombretta

AU - Gonnelli, Angela

AU - Boeri, Enzo

AU - Bonora, Stefano

AU - Ghisetti, Valeria

AU - Francisci, Daniela

AU - Grossi, Paolo

AU - Bagnarelli, Patrizia

AU - Butini, Luca

AU - Del Gobbo, Romana

AU - Giacometti, Andrea

AU - Tacconi, Danilo

AU - Callegaro, Annapaola

AU - Maggiolo, Franco

AU - Zoncada, Alessia

AU - Paolini, Elisabetta

AU - Sighinolfi, Laura

AU - Colao, Grazia

AU - Corsi, Paola

AU - Blanc, Pierluigi

AU - Galli, Luisa

AU - Meraviglia, Paola

AU - Tosti, Andrea

AU - Bruzzone, Bianca

AU - Setti, Maurizio

AU - Penco, Giovanni

AU - Di Biagio, Antonio

AU - Nencioni, Cesira

AU - Pardelli, Riccardo

AU - Arcidiacono, Irene

AU - Degiuli, Alberto

AU - De Gennaro, Michele

AU - Soria, Alessandro

AU - Foc, Alfredo

AU - Latella, Surace

AU - Cosco, Lucio

AU - Malandrin, Sergio

AU - Milini, Paola

AU - Cicconi, Paola

AU - Rusconi, Stefano

AU - Micheli, Valeria

PY - 2018

Y1 - 2018

N2 - Objectives: The aim was to evaluate the evolution of transmitted HIV-1 drug resistance (TDR) prevalence in antiretroviral therapy (ART)-naïve patients from 2006 to 2016. Methods: HIV-1 sequences were retrieved from the Antiviral Response Cohort Analysis (ARCA) database and TDR was defined as detection of at least one mutation from the World Health Organization (WHO) surveillance list. Results: We included protease/reverse transcriptase sequences from 3573 patients; 455 had also integrase sequences. Overall, 68.1% of the patients were Italian, the median CD4 count was 348 cells/μL [interquartile range (IQR) 169–521 cells/μL], and the median viral load was 4.7 log10 HIV-1 RNA copies/mL (IQR 4.1–5.3 log10 copies/mL). TDR was detected in 10.3% of patients: 6% carried mutations to nucleos(t)ide reverse transcriptase inhibitors (NRTIs), 4.4% to nonnucleos(t)ide reverse transcriptase inhibitors (NNRTIs), 2.3% to protease inhibitors (PIs), 0.2% to integrase strand transfer inhibitors (INSTIs) and 2.1% to at least two drug classes. TDR declined from 14.5% in 2006 to 7.3% in 2016 (P = 0.003): TDR to NRTIs from 9.9 to 2.9% (P = 0.003) and TDR to NNRTIs from 5.1 to 3.7% (P = 0.028); PI TDR remained stable. The proportion carrying subtype B virus declined from 76.5 to 50% (P < 0.001). The prevalence of TDR was higher in subtype B vs. non-B (12.6 vs. 4.9%, respectively; P < 0.001) and declined significantly in subtype B (from 17.1 to 8.8%; P = 0.04) but not in non-B subtypes (from 6.1 to 5.8%; P = 0.44). Adjusting for country of origin, predictors of TDR were subtype B [adjusted odds ratio (AOR) for subtype B vs. non-B 2.91; 95% confidence interval (CI) 1.93–4.39; P < 0.001], lower viral load (per log10 higher: AOR 0.86; 95% CI 0.75–0.99; P = 0.03), site in northern Italy (AOR for southern Italy/island vs. northern Italy, 0.61; 95% CI 0.40–0.91; P = 0.01), and earlier calendar year (per 1 year more recent: AOR 0.95; 95% CI 0.91–0.99; P = 0.02). Conclusions: The prevalence of HIV-1 TDR has declined during the last 10 years in Italy.

AB - Objectives: The aim was to evaluate the evolution of transmitted HIV-1 drug resistance (TDR) prevalence in antiretroviral therapy (ART)-naïve patients from 2006 to 2016. Methods: HIV-1 sequences were retrieved from the Antiviral Response Cohort Analysis (ARCA) database and TDR was defined as detection of at least one mutation from the World Health Organization (WHO) surveillance list. Results: We included protease/reverse transcriptase sequences from 3573 patients; 455 had also integrase sequences. Overall, 68.1% of the patients were Italian, the median CD4 count was 348 cells/μL [interquartile range (IQR) 169–521 cells/μL], and the median viral load was 4.7 log10 HIV-1 RNA copies/mL (IQR 4.1–5.3 log10 copies/mL). TDR was detected in 10.3% of patients: 6% carried mutations to nucleos(t)ide reverse transcriptase inhibitors (NRTIs), 4.4% to nonnucleos(t)ide reverse transcriptase inhibitors (NNRTIs), 2.3% to protease inhibitors (PIs), 0.2% to integrase strand transfer inhibitors (INSTIs) and 2.1% to at least two drug classes. TDR declined from 14.5% in 2006 to 7.3% in 2016 (P = 0.003): TDR to NRTIs from 9.9 to 2.9% (P = 0.003) and TDR to NNRTIs from 5.1 to 3.7% (P = 0.028); PI TDR remained stable. The proportion carrying subtype B virus declined from 76.5 to 50% (P < 0.001). The prevalence of TDR was higher in subtype B vs. non-B (12.6 vs. 4.9%, respectively; P < 0.001) and declined significantly in subtype B (from 17.1 to 8.8%; P = 0.04) but not in non-B subtypes (from 6.1 to 5.8%; P = 0.44). Adjusting for country of origin, predictors of TDR were subtype B [adjusted odds ratio (AOR) for subtype B vs. non-B 2.91; 95% confidence interval (CI) 1.93–4.39; P < 0.001], lower viral load (per log10 higher: AOR 0.86; 95% CI 0.75–0.99; P = 0.03), site in northern Italy (AOR for southern Italy/island vs. northern Italy, 0.61; 95% CI 0.40–0.91; P = 0.01), and earlier calendar year (per 1 year more recent: AOR 0.95; 95% CI 0.91–0.99; P = 0.02). Conclusions: The prevalence of HIV-1 TDR has declined during the last 10 years in Italy.

KW - HIV

KW - Health Policy

KW - Infectious Diseases

KW - Pharmacology (medical)

KW - antiretroviral therapy

KW - recent HIV infection

KW - resistance epidemiology

KW - transmitted HIV drug resistance

KW - HIV

KW - Health Policy

KW - Infectious Diseases

KW - Pharmacology (medical)

KW - antiretroviral therapy

KW - recent HIV infection

KW - resistance epidemiology

KW - transmitted HIV drug resistance

UR - http://hdl.handle.net/10807/127194

UR - http://onlinelibrary.wiley.com/journal/10.1111/(issn)1468-1293

U2 - 10.1111/hiv.12640

DO - 10.1111/hiv.12640

M3 - Article

SN - 1464-2662

VL - 19

SP - 619

EP - 628

JO - HIV Medicine

JF - HIV Medicine

ER -

Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo